FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Market Closed - Börse Stuttgart 07:08:54 2024-06-14 am EDT | ||
| 532.4 EUR | -3.37% |
|
| Current month | +21.16% | ||
| 1 month | +24.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 532.4 | -3.37% |
| 24-06-13 | 551 | +0.29% |
| 24-06-12 | 549.4 | +1.26% |
| 24-06-11 | 542.5 | +0.37% |
| 24-06-10 | 540.5 | +2.36% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 07:08 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MC5W13 |
| ISIN | DE000MC5W139 |
| Date issued | 2020-01-21 |
| Strike | 734.9 kr |
| Maturity | Unlimited |
| Parity | 0.06 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 552.6 € |
|---|---|
| Lowest since issue | 4.03 € |
| Spread | 1.26 € |
| Spread % | 0.22% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
991
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.72%
- Stock Market
- Certificates
- Certificat
